Regeneron’s Lynozyfic Gains EC Conditional Approval for Relapsed Multiple Myeloma
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that it has received conditional marketing authorization from the...
T cell engager
EpimAb and Medigene Team Up on TCR-TCE Therapy for Immune-Related Diseases
EpimAb Biotherapeutics, Inc. and Medigene AG (ETR: MDG1) today announced a strategic collaboration agreement to...
Antengene to Boost T Cell Engager Platform with AI Investment and DeepSeek Deployment
China-based biopharma Antengene Corp., Ltd (HKG: 6996) announced plans to increase investment in establishing a...
Keymed and InnoCare Announce Licensing Deal for CD20xCD3 Bispecific Antibody with Prolium
China-based Keymed Biosciences Inc. (HKG: 2162) and InnoCare Pharma (HKG: 9969, SHA: 688428) have jointly...
WuXi Biologics and Candid Therapeutics Ink Global Research Agreement for Trispecific T-cell Engager
China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a...
Candid Therapeutics Expands TCE Portfolio with Strategic Partnerships in Autoimmune Disease Treatment
US-based Candid Therapeutics Inc. is fulfilling its ambition to become a leader in advancing T-cell...
Harbour BioMed Licenses HBM7008 to Cullinan Oncology for US Development
Harbour BioMed (HBM), which operates out of the Netherlands, the United States, and Suzhou, China,...